{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06269484",
            "orgStudyIdInfo": {
                "id": "D4326C00004"
            },
            "organization": {
                "fullName": "AstraZeneca",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK",
            "officialTitle": "A Multicentre, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Combination Compared to Zibotentan Monotherapy, Zibotentan/Dapagliflozin and Zibotentan Monotherapy Compared to Placebo in Participants With Cirrhosis",
            "acronym": "ZEAL UNLOCK",
            "therapeuticArea": [
                "Gastroenterology"
            ],
            "study": "a-phase-iib-study-to-evaluate-the-safety-of-zibotentan-dapagliflozin-in-participants-with-cirrhosis-zeal-unlock"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01-17",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01-17",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-02",
            "studyFirstSubmitQcDate": "2024-02-13",
            "studyFirstPostDateStruct": {
                "date": "2024-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AstraZeneca",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.",
            "detailedDescription": "The study is designed to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin in combination and zibotentan monotherapy as compared to placebo in patients with cirrhosis with or without a history of decompensation. The study will be conducted in approximately 52 study centers in North America, Asia and Europe."
        },
        "conditionsModule": {
            "conditions": [
                "Liver Cirrhosis"
            ],
            "keywords": [
                "Cirrhosis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 66,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment Group 1",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive once daily dose of placebo matching zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks",
                    "interventionNames": [
                        "Drug: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)"
                    ]
                },
                {
                    "label": "Treatment Group 2",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive once daily zibotentan capsule + placebo matching dapagliflozin tablet for 6 weeks",
                    "interventionNames": [
                        "Drug: Zibotentan + placebo (placebo matching dapagliflozin tablet)"
                    ]
                },
                {
                    "label": "Treatment Group 3",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive once daily zibotentan capsule + dapagliflozin tablet 10 mg for 6 weeks",
                    "interventionNames": [
                        "Drug: Zibotentan + dapagliflozin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)",
                    "description": "placebo capsule (matching zibotentan capsule)\n\nplacebo tablet (matching dapagliflozin tablet)",
                    "armGroupLabels": [
                        "Treatment Group 1"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Zibotentan + placebo (placebo matching dapagliflozin tablet)",
                    "description": "zibotentan capsule\n\nplacebo tablet (matching dapagliflozin tablet)",
                    "armGroupLabels": [
                        "Treatment Group 2"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Zibotentan + dapagliflozin",
                    "description": "zibotentan capsule\n\ndapagliflozin 10 mg tablet",
                    "armGroupLabels": [
                        "Treatment Group 3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurence of any of the following components of this composite endpoint: >2kg increase in body weight (office-based), >2 L increase in total body water, increase in 2 or more loop-diuretic equivalents, fluid retention adverse event (AE)",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on a composite endpoint of fluid retention",
                    "timeFrame": "baseline to Week 6"
                },
                {
                    "measure": "Occurence of any of the following components of this composite endpoint: >2kg increase in body weight (office-based), >2 L increase in total body water, increase in 2 or more loop-diuretic equivalents, fluid retention adverse event (AE)",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on a composite endpoint of fluid retention",
                    "timeFrame": "baseline to Week 6"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in body weight (kg) over time course of study",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on body weight",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change in body weight (kg) over time course of study",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on body weight",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change in total dosage of loop-diuretic equivalents use",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on total loop-diuretic equivalents use",
                    "timeFrame": "from baseline to Week 6"
                },
                {
                    "measure": "Change in total dosage of loop-diuretic equivalents use",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on total loop-diuretic equivalents use",
                    "timeFrame": "from baseline to Week 6"
                },
                {
                    "measure": "Occurence of either of the two components of this composite: 1. >3 L increase in total body water volume from baseline to Week 6 2. Increase in 3 or more loop-diuretics equivalents use",
                    "description": "To evaluate the effects of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on the composite of total body water and total dosage of loop-diuretic equivalents",
                    "timeFrame": "from baseline to Week 6"
                },
                {
                    "measure": "Occurence of either of the two components of this composite: 1. >3 L increase in total body water volume from baseline to Week 6 2. Increase in 3 or more loop-diuretics equivalents use",
                    "description": "To evaluate the effects of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on the composite of total body water and total dosage of loop-diuretic equivalents",
                    "timeFrame": "from baseline to Week 6"
                },
                {
                    "measure": "Absolute change in systolic and diastolic blood pressure",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on office-based systolic and diastolic blood pressure",
                    "timeFrame": "from baseline to Week 6"
                },
                {
                    "measure": "Absolute change in systolic and diastolic blood pressure",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on office-based systolic and diastolic blood pressure",
                    "timeFrame": "from baseline to Week 6"
                },
                {
                    "measure": "Change from baseline in body weight",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on body weight",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in total body water",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on total body water",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in extracellular water volume",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on extracellular water volume",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in intracellular water volume",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on intracellular water volume",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in body fat mass",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin versus corresponding zibotentan monotherapy on body fat mass",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in body weight",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on body weight",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in total body water",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on total body water",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in extracellular water volume",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on extracellular water volume",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in intracellular water volume",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on intracellular water volume",
                    "timeFrame": "at Week 6"
                },
                {
                    "measure": "Change from baseline in body fat mass",
                    "description": "To evaluate the effect of zibotentan/dapagliflozin and zibotentan monotherapy versus placebo on body fat mass",
                    "timeFrame": "at Week 6"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n\u2265 18 and \u2264 80 years of age at the time of signing the informed consent.\n\nClinical and/or histological diagnosis of cirrhosis.\n\nNote: Either history of decompensation or compensated cirrhosis with signs of CSPH, including varices at endoscopy or collaterals at imaging (within 12 months prior to screening), and/or liver stiffness using vibration controlled elastography, liver stiffness \\> 25 kPa or \\> 21 kPa, and platelets \\< 150 \u00d7 10\\^99 (at time of screening).\n\nModel for end stage liver disease score (MELD) \\< 15.\n\nChild-Pugh score \\< 10.\n\nNo ascites or ascites up to grade 2 without change in diuretic treatment within the last month prior to first dose of study intervention and no paracentesis within the last month.\n\nNo evidence of worsening of hepatic function (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status) within the last month prior to dosing, as determined by the investigator or usual practitioner.\n\nNo current or prior (within 1 month of enrolment) medical treatment with an SGLT2 inhibitor or endothelin receptor antagonist.\n\nOn no or a stable dose of beta blockers, with no major dose changes within 1 month prior to the first dose of study intervention.\n\nMales or females of non-childbearing potential:\n\nMale participants must be surgically sterile, abstinent, or must use in conjunction with their female partner a highly effective method of contraception from the time they sign the informed consent document and for 3 months after the last dose of study intervention to prevent pregnancy in a partner. In addition, the male participant should use a condom for the duration of the study and for 3 months after the last dose of study intervention. Male participants must not donate or bank sperm during the same period.\n\nHighly effective birth control methods are defined as those that can achieve a failure rate of less than 1% per year when used consistently and correctly.\n\nFemale participants must be of non-childbearing potential confirmed at screening by fulfilling one of the following criteria:\n\nPost-menopausal: defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments; and also FSH levels in the post-menopausal range by central laboratory (Note: The post-menopausal range must be checked against the specific FSH assay used). In the absence of 12 months of amenorrhoea, a single FSH measurement is insufficient to define post-menopausal criteria. In case of perimenopause or infrequent periods with variable levels of FSH, women should be considered of childbearing potential and, therefore, not eligible for participation in this study.\n\nDocumentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.\n\nFemale participants must have a negative pregnancy test at screening and must not be lactating.\n\nCapable of giving signed informed consent as described in Appendix A, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nProvision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.\n\nProvision of signed and dated written Optional Genomics Initiative Research Information and Consent Form prior to collection of samples for optional genomics initiative research that supports Genomic Initiative.\n\nExclusion criteria:\n\nAny evidence of a clinically significant disease, which in the investigator's opinion makes it undesirable for the participant to participate in the study.\n\nAlanine aminotransferase/transaminase or AST \u2265 150 U/L and/or total bilirubin\n\n\u2265 3 \u00d7 ULN.\n\nInternational normalised ratio \\> 1.7.\n\nSerum/plasma levels of albumin \u2264 28 g/L.\n\nPlatelet count \\< 50 \u00d7 109L.\n\nAcute kidney injury (AKI) within 3 months of screening.\n\nHistory of encephalopathy of West Haven Grade 2 or higher\n\nHistory of variceal haemorrhage within 6 months prior to screening.\n\nAny history of hepatocellular carcinoma.\n\nAny history of portal venous thrombosis.\n\nLiver transplant or expected liver transplantation within 6 months of screening.\n\nHistory of TIPS or a planned TIPS within 6 months from enrolment into the study.\n\nPositive alcohol breath test or screen for drugs of abuse (excluding drugs prescribed by the participants' usual physician) at screening.\n\nOngoing or history of significant use of alcohol expected to preclude correct adherence to study procedures (For details, refer to Section 5.3.2).\n\nActive treatment for HCV within the last 1 year or HBV anti-viral therapy for less than 1 year.\n\nActive urinary tract infection or genital infection.\n\nUncontrolled diabetes mellitus (HbA1c \\> 8.5% or \\> 69 mmol/mol within the last month).\n\nParticipants with T1DM.\n\nRenal transplant or chronic renal replacement therapy or short-term dialysis within the previous 6 months.\n\neGFR \\< 60 mL/min/1.73m2 (eGFRcr\\[AS\\]).\n\nAcute coronary syndrome events within 3 months prior to screening.\n\nOrthostatic hypotension or hypotension (systolic blood pressure \\< 95 mmHg or diastolic blood pressure \\< 60 mmHg).\n\nNew York Heart Association functional heart failure Class III or IV or patients with unstable heart failure requiring hospitalisation for optimisation of heart failure treatment and who are not yet stable on heart failure therapy within 6 months prior to screening.\n\nHeart failure due to cardiomyopathies that would primarily require specific other treatment.\n\nHigh output heart failure (eg, due to hyperthyroidism or Paget's disease).\n\nHeart failure due to primary cardiac valvular disease/dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.\n\nParticipants treated with strong CYP3A4 inhibitor or strong or moderate CYP3A4 inducer within 14 days (St. John's Wort: 21 days) of study intervention administration; this includes grapefruit and grapefruit juice, if consumed more often than occasionally, or, in larger quantities.\n\nHistory or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin), zibotentan, or drugs with a similar chemical structure to zibotentan.\n\nAny clinically significant chronic disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment) which, as judged by the investigator, might put the participant at risk because of participation in the study, or probable alternative primary reason for participant's symptoms in judgment of investigator.\n\nAcute liver injury caused by drug toxicity or by an infection.\n\nImplanted electronic device such as pacemaker.\n\nInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study centre).\n\nJudgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.\n\nMale participant in a sexually active relation with pregnant or breastfeeding partner.\n\nVulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.\n\nExclusion Criteria for Participants Consenting to Optional Genetic Sampling:\n\nPrevious allogeneic bone marrow transplant.\n\nNon-leukocyte depleted whole blood transfusion in 120 days of genetic sample collection.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AstraZeneca Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-877-240-9479",
                    "email": "information.center@astrazeneca.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Englewood",
                    "state": "Colorado",
                    "zip": "80113",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.64777,
                        "lon": -104.98776
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Adelaide",
                    "zip": "5000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -34.92866,
                        "lon": 138.59863
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Kogarah",
                    "zip": "2217",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -33.98333,
                        "lon": 151.11667
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Mitcham",
                    "zip": "3132",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.81667,
                        "lon": 145.2
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Edegem",
                    "zip": "2650",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.15662,
                        "lon": 4.44504
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Mechelen",
                    "zip": "2800",
                    "country": "Belgium",
                    "geoPoint": {
                        "lat": 51.02574,
                        "lon": 4.47762
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Liberec",
                    "zip": "460 63",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 50.76711,
                        "lon": 15.05619
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Mlad\u00e1 Boleslav",
                    "zip": "293 01",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 50.41135,
                        "lon": 14.90318
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Plze\u0148",
                    "zip": "323 00",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 49.74747,
                        "lon": 13.37759
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Praha 4",
                    "zip": "140 21",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 50.08804,
                        "lon": 14.42076
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Aachen",
                    "zip": "52074",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.77664,
                        "lon": 6.08342
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Kiel",
                    "zip": "24146",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 54.32133,
                        "lon": 10.13489
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Leipzig",
                    "zip": "04103",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 51.33962,
                        "lon": 12.37129
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Tuebingen",
                    "zip": "72076",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 48.52266,
                        "lon": 9.05222
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Milano",
                    "zip": "20122",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Padova",
                    "zip": "35128",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.40797,
                        "lon": 11.88586
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Roma",
                    "zip": "00168",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Gifu-shi",
                    "zip": "500-8513",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.42291,
                        "lon": 136.76039
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Iizuka-shi",
                    "zip": "820-8505",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 33.63654,
                        "lon": 130.68678
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Kawasaki-shi",
                    "zip": "215-0026",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.52056,
                        "lon": 139.71722
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Kitakyusyu-shi",
                    "zip": "806-8501",
                    "country": "Japan"
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Nagaoka-shi",
                    "zip": "940-2085",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 37.45,
                        "lon": 138.85
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Niigata-shi",
                    "zip": "951-8520",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 37.88637,
                        "lon": 139.00589
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Sapporo-shi",
                    "zip": "006-8555",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 43.06667,
                        "lon": 141.35
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Yokohama-shi",
                    "zip": "236-0004",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Bydgoszcz",
                    "zip": "85-794",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 53.1235,
                        "lon": 18.00762
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Katowice",
                    "zip": "40-081",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.25841,
                        "lon": 19.02754
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Krak\u00f3w",
                    "zip": "31-513",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Mys\u0142owice",
                    "zip": "41-400",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.20745,
                        "lon": 19.16668
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Pozna\u0144",
                    "zip": "61-848",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 52.40692,
                        "lon": 16.92993
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Wroc\u0142aw",
                    "zip": "52-210",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 51.1,
                        "lon": 17.03333
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Bratislava",
                    "zip": "83104",
                    "country": "Slovakia",
                    "geoPoint": {
                        "lat": 48.14816,
                        "lon": 17.10674
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nitra",
                    "zip": "950 01",
                    "country": "Slovakia",
                    "geoPoint": {
                        "lat": 48.30763,
                        "lon": 18.08453
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Trnava",
                    "zip": "91702",
                    "country": "Slovakia",
                    "geoPoint": {
                        "lat": 48.37741,
                        "lon": 17.58723
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Aberdeen",
                    "zip": "AB25 2ZN",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 57.14369,
                        "lon": -2.09814
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Hull",
                    "zip": "HU3 2KZ",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.7446,
                        "lon": -0.33525
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Ipswich",
                    "zip": "IP4 5PD",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.05917,
                        "lon": 1.15545
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "London",
                    "zip": "SE5 9RS",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Nottingham",
                    "zip": "NG7 2UH",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.9536,
                        "lon": -1.15047
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal\n\nVivli.org. All requests will be evaluated as per the AZ disclosure commitment:\n\nhttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.\n\n\"Yes\", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",
            "accessCriteria": "When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000529054",
                    "term": "Dapagliflozin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000077203",
                    "term": "Sodium-Glucose Transporter 2 Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M348449",
                    "name": "Dapagliflozin",
                    "asFound": "10 minutes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1691",
                    "name": "Sodium-Glucose Transporter 2 Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}